Merck (MRK) Short-term Investments (2009 - 2026)

Merck (MRK) has reported Short-term Investments for 17 consecutive years, with $375.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 37.4% year-over-year to $375.0 million; the TTM figure through Mar 2026 stood at $375.0 million (down 37.4% YoY), while the FY2024 annual figure was $447.0 million, up 77.38% from the prior year.
• Short-term Investments grew to $375.0 million in Q1 2026 per MRK's latest filing, from $45.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $718.0 million in Q2 2023 and bottomed at $40.0 million in Q1 2024.
• Historically, Short-term Investments has averaged $361.0 million across 5 years, with a median of $375.0 million in 2026.
• Annual changes were most pronounced in 2024 — Short-term Investments plunged 94.12% — and 2025, when it surged 1397.5%.
• Merck's Short-term Investments stood at $498.0 million in 2022, then sank by 49.4% to $252.0 million in 2023, then surged by 77.38% to $447.0 million in 2024, then slumped by 89.93% to $45.0 million in 2025, then jumped by 733.33% to $375.0 million in 2026.
• Business Quant data shows MRK's Short-term Investments at $375.0 million in Q1 2026, $45.0 million in Q3 2025, and $615.0 million in Q2 2025.